Part of Thermo Fisher Scientific
HOME >
EDG1 DISCONTINUED DISCONTINUED ANTIBODIES > EDG1 DISCONTINUED DISCONTINUED POLYCLONAL ANTIBODY OPA1-15003Z
Anti-EDG1 DISCONTINUED DISCONTINUED Polyclonal Antibody
Printable Datasheet
Synonyms:
Sphingolipid Receptor 1, Endothelial Differentiation Gene 1, EDG1, S1PR1
| Details | |
| Host / Isotype: | Rabbit |
| Class: | Polyclonal |
| Type: | Antibody |
| Species Reactivity: | Human (Hu) |
| Immunogen: | Synthetic peptide, KLH conjugated, corresponding to the to the C-terminus domain near resiude #350 of human S1P1. |
| Ordering Information | ||||
| Pierce Anti-EDG1 DISCONTINUED DISCONTINUED Polyclonal Antibody | ||||
| Product Number | Pkg. Size | Price | Purchase | |
| OPA1-15003Z | 25 µg | $0.00 | ||
| Storage: | -20º C, Avoid Freeze/Thaw Cycles |
| Form: | 25 µg of antibody in PBS, PH 7.7 containing 0.01% sodium azide. |
| Applications | Dilution |
| Immunohistochemistry (Paraffin) (IHC (P)) | 1:100 |
| Product Specific Information |
| OPA1-15003Z detects S1P1 from human samples. This antibody is expected to react with rhesus monkey, chimp, cat, pig, cow, mice, and rat S1P1 due to sequence homology. OPA1-15003Z has been successfully used in immunohistochemistry procedures. By immunohistochemistry, OPA1-15003Z detects S1P1 in formalin fixed, paraffin embedded human tissues. The OPA1-15003Z immunogen is a ynthetic peptide, KLH conjugated, corresponding to the to the C-terminus of human S1P1. This antibody detects an epitope near residue #350 of the human sequence. Figure 1 shows a staining of S1P1 in human cells using OPA1-15003Z. |
| General Information |
| S1P1 transcripts have been reported to be present in embryonic and adult brain, lung alveolar macrophages, vascular smooth muscle cells, endothelial cells, fibroblasts, melanocytes, and TAg-Jurkat T cells, but to be absent from breast cancer cell lines. G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist. All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms. An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors. Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs. This "turn-off" activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates. Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively. |
(This product is for In Vitro experimental use only.)
 |
|||||||||||||
PO
Box 117, Rockford, IL 61105 USA |
 |
 |
